Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin

Croci et al., International Journal of Biomaterials, doi:10.1155/2016/8043983
May 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
In Vitro study of liposomal formulations of ivermectin showing up to 5 times lower cytotoxicity and increased antiviral activity in Dengue strains.
68 preclinical studies support the efficacy of ivermectin for COVID-19:
Ivermectin, better known for antiparasitic activity, is a broad spectrum antiviral with activity against many viruses including H7N766, Dengue32,67,68, HIV-168, Simian virus 4069, Zika32,70,71, West Nile71, Yellow Fever72,73, Japanese encephalitis72, Chikungunya73, Semliki Forest virus73, Human papillomavirus52, Epstein-Barr52, BK Polyomavirus74, and Sindbis virus73.
Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins66,68,69,75, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing33, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination36,76, shows dose-dependent inhibition of wildtype and omicron variants31, exhibits dose-dependent inhibition of lung injury56,61, may inhibit SARS-CoV-2 via IMPase inhibition32, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation5, inhibits SARS-CoV-2 3CLpro49, may inhibit SARS-CoV-2 RdRp activity24, may minimize viral myocarditis by inhibiting NF-κB/p65-mediated inflammation in macrophages55, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation77, shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-1954,78, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage4, may minimize SARS-CoV-2 induced cardiac damage35,43, increases Bifidobacteria which play a key role in the immune system79, has immunomodulatory46 and anti-inflammatory65,80 properties, and has an extensive and very positive safety profile81.
Croci et al., 8 May 2022, peer-reviewed, 7 authors. Contact: nas@unife.it.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperIvermectinAll
Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin
Romina Croci, Elisabetta Bottaro, Kitti Wing Ki Chan, Satoru Watanabe, Margherita Pezzullo, Eloise Mastrangelo, Claudio Nastruzzi
International Journal of Biomaterials, doi:10.1155/2016/8043983
RNA virus infections can lead to the onset of severe diseases such as fever with haemorrhage, multiorgan failure, and mortality. The emergence and reemergence of RNA viruses continue to pose a significant public health threat worldwide with particular attention to the increasing incidence of flaviviruses, among others Dengue, West Nile Virus, and Yellow Fever viruses. Development of new and potent antivirals is thus urgently needed. Ivermectin, an already known antihelminthic drug, has shown potent effects in vitro on Flavivirus helicase, with EC 50 values in the subnanomolar range for Yellow Fever and submicromolar EC 50 for Dengue Fever, Japanese encephalitis, and tick-borne encephalitis viruses. However ivermectin is hampered in its application by pharmacokinetic problems (little solubility and high cytotoxicity). To overcome such problems we engineered different compositions of liposomes as ivermectin carriers characterizing and testing them on several cell lines for cytotoxicity. The engineered liposomes were less cytotoxic than ivermectin alone and they showed a significant increase of the antiviral activity in all the Dengue stains tested (1, 2, and S221). In the current study ivermectin is confirmed to be an effective potential antiviral and liposomes, as drug carriers, are shown to modulate the drug activity. All together the results represent a promising starting point for future improvement of ivermectin as antiviral and its delivery.
Competing Interests The authors declare that there are no competing interests regarding the publication of this paper.
References
Alvinerie, Escudero, Sutra, Eeckhoutte, Galtier, The pharmacokinetics of moxidectin after oral and subcutaneous administration to sheep, Veterinary Research
Bassissi, Lespine, Alvinerie, Assessment of a liposomal formulation of ivermectin in rabbit after a single subcutaneous administration, Parasitology Research
Bollati, Alvarez, Assenberg, Structure and functionality in flavivirus NS-proteins: perspectives for drug design, Antiviral Research
Gonzalez Canga, Sahagun Prieto, Diez Liébana, Martínez, Vega et al., The pharmacokinetics and interactions of ivermectin in humans-a mini-review, AAPS Journal
Guzman, Kouri, Dengue haemorrhagic fever integral hypothesis: confirming observations, 1987-2007, Transactions of the Royal Society of Tropical Medicine and Hygiene
Kuhn, Zhang, Rossmann, Structure of dengue virus: implications for flavivirus organization, maturation, and fusion, Cell
Lindenbach, Rice, Molecular biology of flaviviruses, Advances in Virus Research
Low, Ooi, Tolfvenstam, Early dengue infection and outcome study (EDEN)-study design and preliminary findings, Annals of the Academy of Medicine Singapore
Mastrangelo, Mazzitelli, Fabbri, Delivery of suramin as an antiviral agent through liposomal systems, ChemMedChem
Mastrangelo, Pezzullo, De Burghgraeve, Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, Journal of Antimicrobial Chemotherapy
Rocha-Pereira, Jochmans, Debing, Verbeken, Nascimento et al., The viral polymerase inhibitor 2 󸀠 -cmethylcytidine inhibits norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model, Journal of Virology
Tay, Fraser, Chan, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antiviral Research
Vasilakis, Weaver, The history and evolution of human dengue emergence, Advances in Virus Research
Watanabe, Chan, Dow, Ooi, Low et al., Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: the search for a window for potential therapeutic efficacy, Antiviral Research
{ 'indexed': {'date-parts': [[2022, 4, 23]], 'date-time': '2022-04-23T16:25:36Z', 'timestamp': 1650731136751}, 'reference-count': 14, 'publisher': 'Hindawi Limited', 'license': [ { 'start': { 'date-parts': [[2016, 1, 1]], 'date-time': '2016-01-01T00:00:00Z', 'timestamp': 1451606400000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'http://creativecommons.org/licenses/by/4.0/'}], 'funder': [ { 'DOI': '10.13039/501100004963', 'name': 'Seventh Framework Programme', 'doi-asserted-by': 'publisher', 'award': ['260644', 'CRADA10262012']}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2016]]}, 'abstract': '<jats:p>RNA virus infections can lead to the onset of severe diseases such as fever with ' 'haemorrhage, multiorgan failure, and mortality. The emergence and reemergence of RNA viruses ' 'continue to pose a significant public health threat worldwide with particular attention to ' 'the increasing incidence of flaviviruses, among others Dengue, West Nile Virus, and Yellow ' 'Fever viruses. Development of new and potent antivirals is thus urgently needed. Ivermectin, ' 'an already known antihelminthic drug, has shown potent effects<jats:italic>in ' 'vitro</jats:italic>on<jats:italic>Flavivirus</jats:italic>helicase, with ' 'EC<jats:sub>50</jats:sub>values in the subnanomolar range for Yellow Fever and submicromolar ' 'EC<jats:sub>50</jats:sub>for Dengue Fever, Japanese encephalitis, and tick-borne encephalitis ' 'viruses. However ivermectin is hampered in its application by pharmacokinetic problems ' '(little solubility and high cytotoxicity). To overcome such problems we engineered different ' 'compositions of liposomes as ivermectin carriers characterizing and testing them on several ' 'cell lines for cytotoxicity. The engineered liposomes were less cytotoxic than ivermectin ' 'alone and they showed a significant increase of the antiviral activity in all the Dengue ' 'stains tested (1, 2, and S221). In the current study ivermectin is confirmed to be an ' 'effective potential antiviral and liposomes, as drug carriers, are shown to modulate the drug ' 'activity. All together the results represent a promising starting point for future ' 'improvement of ivermectin as antiviral and its delivery.</jats:p>', 'DOI': '10.1155/2016/8043983', 'type': 'journal-article', 'created': {'date-parts': [[2016, 5, 8]], 'date-time': '2016-05-08T21:00:51Z', 'timestamp': 1462741251000}, 'page': '1-15', 'source': 'Crossref', 'is-referenced-by-count': 26, 'title': 'Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin', 'prefix': '10.1155', 'volume': '2016', 'author': [ { 'given': 'Romina', 'family': 'Croci', 'sequence': 'first', 'affiliation': [ { 'name': 'Department of Bioscience, University of Milan, 20133 Milan, ' 'Italy'}]}, { 'given': 'Elisabetta', 'family': 'Bottaro', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Life Sciences and Biotechnology, University of ' 'Ferrara, 44121 Ferrara, Italy'}]}, { 'given': 'Kitti Wing Ki', 'family': 'Chan', 'sequence': 'additional', 'affiliation': [ { 'name': 'Program in Emerging Infectious Diseases, Duke-NUS Graduate ' 'Medical School, Singapore 169857'}]}, { 'given': 'Satoru', 'family': 'Watanabe', 'sequence': 'additional', 'affiliation': [ { 'name': 'Program in Emerging Infectious Diseases, Duke-NUS Graduate ' 'Medical School, Singapore 169857'}]}, { 'given': 'Margherita', 'family': 'Pezzullo', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Bioscience, University of Milan, 20133 Milan, ' 'Italy'}]}, { 'given': 'Eloise', 'family': 'Mastrangelo', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Bioscience, University of Milan, 20133 Milan, ' 'Italy'}, { 'name': 'Institute of Biophysics, National Research Council, 20133 Milan, ' 'Italy'}]}, { 'given': 'Claudio', 'family': 'Nastruzzi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Life Sciences and Biotechnology, University of ' 'Ferrara, 44121 Ferrara, Italy'}]}], 'member': '98', 'reference': [ { 'key': '1', 'doi-asserted-by': 'crossref', 'first-page': '1', 'volume': '72', 'year': '2008', 'journal-title': 'Advances in Virus Research', 'DOI': '10.1016/S0065-3527(08)00401-6'}, {'key': '2', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.trstmh.2008.03.001'}, {'key': '3', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/s0092-8674(02)00660-8'}, {'key': '4', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S0065-3527(03)59002-9'}, {'key': '5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2009.11.009'}, {'key': '6', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dks147'}, { 'issue': '2', 'key': '9', 'first-page': '113', 'volume': '29', 'year': '1998', 'journal-title': 'Veterinary Research'}, {'key': '10', 'doi-asserted-by': 'publisher', 'DOI': '10.1208/s12248-007-9000-9'}, {'key': '11', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cmdc.201300563'}, { 'issue': '11', 'key': '12', 'first-page': '783', 'volume': '35', 'year': '2006', 'journal-title': 'Annals of the Academy of Medicine Singapore'}, {'key': '15', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2015.12.008'}, {'key': '16', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/jvi.02064-13'}, {'key': '17', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00436-005-0073-z'}, {'key': '18', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2013.06.002'}], 'container-title': 'International Journal of Biomaterials', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'http://downloads.hindawi.com/journals/ijbm/2016/8043983.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://downloads.hindawi.com/journals/ijbm/2016/8043983.xml', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'http://downloads.hindawi.com/journals/ijbm/2016/8043983.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2017, 6, 24]], 'date-time': '2017-06-24T13:08:15Z', 'timestamp': 1498309695000}, 'score': 1, 'resource': {'primary': {'URL': 'http://www.hindawi.com/journals/ijbm/2016/8043983/'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2016]]}, 'references-count': 14, 'alternative-id': ['8043983', '8043983'], 'URL': 'http://dx.doi.org/10.1155/2016/8043983', 'relation': {}, 'ISSN': ['1687-8787', '1687-8795'], 'subject': ['Biomedical Engineering', 'Biomaterials'], 'container-title-short': 'International Journal of Biomaterials', 'published': {'date-parts': [[2016]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit